---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-003374"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-09-25T23:59:59+00:00"
generated_at: "2026-05-17T05:43:04.774533+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics regains Nasdaq compliance; subject to one-year monitor

## Summary
- Received Nasdaq compliance letter on Sep 23, 2025 for equity (≥$2.5M) and minimum bid price ($1.00) requirements.
- Financing transactions increased shareholders' equity by $10.3M to ~$9.41M as of Sep 15, 2025.
- 1-for-15 reverse stock split on Jul 29, 2025 brought bid price above $1.00.
- Subject to mandatory panel monitor until Sep 23, 2026; any future non-compliance may lead to immediate delisting.

## SEC filing metadata
- accession: 0001178913-25-003374
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-09-25T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003374/0001178913-25-003374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325003374/zk2533805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-003374
- JSON: https://secwatch.observer/filing/0001178913-25-003374.json
- Plain text: https://secwatch.observer/filing/0001178913-25-003374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.